Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
13 Dezembro 2021 - 06:05PM
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in
developing novel, controllable cellular immunotherapies for
cancers, today announced that it has received a letter from the
Listing Qualifications Hearings Department of The Nasdaq Stock
Market LLC notifying the company that it has regained compliance
with Listing Rule 5550(b)(1), which requires stockholders’ equity
of at least $2.5 million for continued listing of the company’s
common stock. Accordingly, the Company is now in compliance with
the continued listing requirements of The Nasdaq Capital Market.
The notification follows the company’s recent completion of its
private placement of equity securities for gross proceeds of
approximately $35.0 million, before deducting placement agent
commissions and offering expenses payable by the Company.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving
to deliver cures through controllable cell therapies. The company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates,
BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell
products capable of overriding key immune inhibitory mechanisms.
More information about Bellicum can be found at www.bellicum.com or
follow us on Twitter or LinkedIn.
Investors:Robert H. UhlManaging DirectorWestwicke
ICR858-356-5932Robert.uhl@westwicke.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024